US FDA Reviewing Possible Heart Risks with Roche, Novartis Corporation Asthma Drug

Reuters -- U.S. regulators are reviewing if Roche and Novartis AG's asthma drug Xolair may be linked to an increased risk of heart attacks and strokes, health officials said on Thursday.